Sienna Biopharmaceuticals, Inc.
SNNAQ · OTC
9/30/2019 | 6/30/2019 | 3/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $5 | $7 | $11 |
| G&A Expenses | $5 | $3 | $9 | $9 |
| SG&A Expenses | $5 | $3 | $9 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $8 | $16 | $20 |
| Operating Income | -$6 | -$8 | -$16 | -$20 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$1 | -$1 | $0 |
| Pre-Tax Income | -$9 | -$8 | -$16 | -$19 |
| Tax Expense | -$5 | $0 | $0 | -$0 |
| Net Income | -$4 | -$8 | -$16 | -$19 |
| % Margin | – | – | – | – |
| EPS | -0.13 | -0.27 | -0.67 | -0.93 |
| % Growth | 51.9% | 59.7% | 28% | – |
| EPS Diluted | -0.13 | -0.27 | -0.67 | -0.93 |
| Weighted Avg Shares Out | 31 | 30 | 25 | 21 |
| Weighted Avg Shares Out Dil | 31 | 30 | 25 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9 | -$8 | -$16 | -$20 |
| % Margin | – | – | – | – |